摘要
目的 探讨Eph受体酪氨酸激酶A2 (EphA2) 和上皮粘连素 (E cadherin) 在前列腺癌 (CaP) 中的表达及其意义。方法 用免疫组化SP法检测EphA2和E cadherin蛋白在44例CaP、23例高分级前列腺上皮内瘤 (PIN)及25例良性前列腺组织中的表达情况。结果 在CaP中EphA2表达显著高于PIN (P<0. 01), 两者均显著高于良性前列腺组织 (均P<0 .01)。CaP中E cadherin表达显著低于PIN及良性组织 (均 P<0. 01), 后两者间无显著性差异(P>0 .05)。EphA2高表达和E cadherin低表达与 CaP病理分级、临床分期及癌症转移密切相关。EphA2 与 E cad herin表达呈负相关。结论 EphA2可作为CaP的早期诊断指标和治疗的新靶点。E cadherin可与 EphA2 结合作为判断CaP恶性程度及预后的指标。
Objective To investigate the expression of Eph tyrosine kinase receptor A2 (EphA2) and epithelial cadherin (E-cadherin) in prostate cancer (CaP) and its significance. Methods The expression levels of EphA2 and E-cadherin proteins were determined by immunohistochemical analysis (SP method) in 44 cases of CaP,23 cases of high-grade prostatic intraepithelial neoplasia (PIN) and 25 cases of benign prostatic tissue. Results The expression levels of EphA2 were significantly higher in CaP than in PIN (P<0.01).The expression levels of EphA2 in CaP and PIN were significantly higher than those in benign prostatic tissue (P<0.01). The positive rate of E-cadherin in CaP was significantly lower than that in PIN and benign prostatic tissue (P<0.01). The overexpression of EphA2 and the low expression of E-cadherin were positively correlated with clinical stage, pathological grade and metastasis of prostate cancer. The expression of EphA2 was inversely correlated with that of E-cadherin. Conclusion EphA2 could be used as a parameter for the early diagnosis of CaP and a novel target for CaP treatment.Together with E-cadherin,EphA2 may be a good marker to monitor the malignant degree and the prognosis of CaP.
出处
《华中科技大学学报（医学版）》
CAS
CSCD
北大核心
2005年第1期51-54,共4页
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金
*国家自然科学基金资助项目 (No. 30070756)
